CA2929286A1 - Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glutamic acid - Google Patents

Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glutamic acid Download PDF

Info

Publication number
CA2929286A1
CA2929286A1 CA2929286A CA2929286A CA2929286A1 CA 2929286 A1 CA2929286 A1 CA 2929286A1 CA 2929286 A CA2929286 A CA 2929286A CA 2929286 A CA2929286 A CA 2929286A CA 2929286 A1 CA2929286 A1 CA 2929286A1
Authority
CA
Canada
Prior art keywords
mepe
mice
syndrome
treated
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2929286A
Other languages
English (en)
French (fr)
Inventor
Lawrence Irwin Glass
Michael John Bickerdike
Michael Frederick Snape
Patricia Perez DE COGRAM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neuren Pharmaceuticals Ltd
Original Assignee
Neuren Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuren Pharmaceuticals Ltd filed Critical Neuren Pharmaceuticals Ltd
Publication of CA2929286A1 publication Critical patent/CA2929286A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2929286A 2012-11-28 2013-11-26 Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glutamic acid Abandoned CA2929286A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261730829P 2012-11-28 2012-11-28
US61/730,829 2012-11-28
PCT/US2013/072049 WO2014085480A1 (en) 2012-11-28 2013-11-26 Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glutamic acid

Publications (1)

Publication Number Publication Date
CA2929286A1 true CA2929286A1 (en) 2014-06-05

Family

ID=50828422

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2929286A Abandoned CA2929286A1 (en) 2012-11-28 2013-11-26 Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glutamic acid

Country Status (6)

Country Link
EP (1) EP2928300A4 (ja)
JP (1) JP2016506380A (ja)
AU (1) AU2013352294A1 (ja)
BR (1) BR112015012506A2 (ja)
CA (1) CA2929286A1 (ja)
WO (1) WO2014085480A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107847194B (zh) * 2014-06-30 2020-11-24 塞罗拉公司 使有操作延迟的pc与有实时时钟的微控制器同步的系统
US20210315914A1 (en) * 2018-08-10 2021-10-14 New York University Use of igf-2 receptor agonist ligands for treatment of angelman syndrome and autism

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8637567B2 (en) * 2001-05-24 2014-01-28 Neuren Pharmaceuticals Ltd. Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamic acid
DE60232880D1 (de) * 2001-05-24 2009-08-20 Neuren Pharmaceuticals Ltd Gpe-analoga und peptidomimetika
JP5289765B2 (ja) * 2004-09-20 2013-09-11 マウント シナイ スクール オブ メディシン 自閉症、強迫神経症、および衝動性の治療のためのメマンチン（ナメンダ）の使用
JP2008545697A (ja) * 2005-05-23 2008-12-18 ニューレン ファーマシューティカルズ リミテッド グリシル−プロリル−グルタメートの類縁体
WO2007106555A2 (en) * 2006-03-14 2007-09-20 Neuren Pharmaceuticals Limited Oral formulations of glycyl-2-methylprolyl-glutamate
PL2083811T3 (pl) * 2006-11-22 2017-05-31 Clinical Research Associates, Llc Sposoby leczenia zespołu downa, zespołu łamliwego chromosomu x oraz autyzmu
AU2008262387A1 (en) * 2007-06-08 2008-12-18 Massachusetts Institute Of Technology IGF for the treatment of Rett Syndrome and synaptic disorders
EP2571515B1 (en) * 2010-05-17 2016-11-30 Icahn School of Medicine at Mount Sinai Methods and assays for treating subjects with shank3 deletion, mutation or reduced expression
HUE036637T2 (hu) * 2011-01-27 2018-07-30 Neuren Pharmaceuticals Ltd Autizmus spektrumbetegségek kezelése glicil-L-2-metilprolil-L-glutaminsavval

Also Published As

Publication number Publication date
EP2928300A1 (en) 2015-10-14
JP2016506380A (ja) 2016-03-03
EP2928300A4 (en) 2016-07-13
BR112015012506A2 (pt) 2017-07-11
AU2013352294A1 (en) 2015-07-09
WO2014085480A1 (en) 2014-06-05

Similar Documents

Publication Publication Date Title
JP6640275B2 (ja) グリシル−ｌ−２−メチルプロリル−ｌ−グルタミン酸を用いる自閉症スペクトラム障害の治療
US11197856B2 (en) Bicyclic compounds and methods for their use in treating autism
US20150224164A1 (en) Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glumatic acid
CA2929286A1 (en) Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glutamic acid
US20190091284A1 (en) Amidated Dopamine Neuron Stimulating Peptides for CNS Dopaminergic Upregulation
US20180117113A1 (en) Amidated Dopamine Neuron Stimulating Peptide Restoration of Mitochondrial Activity
Schaan Profes The role of autophagy in the growth and guidance of midbrain dopaminergic neurons
Mantash Cellular and molecular aspects of cell therapy in mouse models of Parkinson's disease and traumatic brain injury

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20171128